Governance
CIRS is governed by its own dedicated advisory boards made up of external international experts from academia, industry, regulatory agencies and HTA bodies.
The Scientific Advisory Council (SAC) and HTA Steering Committee advise CIRS on workshops, special projects, publications as well as the research programme, to ensure neutrality and that the areas are unbiased and the programme meets the needs to all stakeholders. The selection of Committee Members and Chairs is set out in the Terms of Reference of each committee.
| Scientific Advisory Council (SAC) | ||
|---|---|---|
| Chair: Adjunct Prof John Skerritt | Enterprise Professor, Health Research Impact at the University of Melbourne, Australia and an Adjunct Professor, Faculty of Medicine and Health of the University of Sydney, Australia | |
| Vice-Chair: Prof Hans-Georg Eichler | Consulting Physician of the Association of Austrian Social Insurance Institutions | |
| Dr Claus Bolte | Chief Medical Officer, Swissmedic | |
| Dr Harald Enzmann | Chair, European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) | |
| Prof John Lim | Executive Director of Centre of Regulatory Excellence (CoRE), Duke-NUS Medical School and Chairman, Consortium for Clinical Research & Innovation, Singapore | |
| Dr Theresa Mullin | Director, Office of Strategic Programs, US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) | |
| Dr Brian O’Rourke | Former CEO and President, Canadian Agency for Drugs and Technologies in Health (CADTH) | |
| Dr Charles Preston | Senior Program Officer, Regulatory Affairs , Bill and Melinda Gates Foundation, USA | |
| Karen Reynolds | Director General, Pharmaceutical Drugs Directorate, Health Canada | |
| Dr Xie Songmei | Director of Clinical Department Center for Drug Evaluation, National Medical Products Administration (NMPA), China | |
| Dr Steffen Thirstrup | Chief Medical Officer, EMA | |
| Naoyuki Yasuda | Associate Executive Director for International Programs, Pharmaceuticals and Medical Devices Agency (PMDA), Japan | |
| Dr Fabio Bisordi | Global Head International Regulatory Policy, Roche | |
| Jeffery Francer | Vice President, Head of Global Regulatory Policy & Strategy, Eli Lilly & Company | |
| Adrian Griffin | Vice President for HTA Policy, Johnson & Johnson | |
| Dr David Jefferys | Senior Vice President, Head of Global Regulatory, Eisai Europe | |
| Judith Macdonald | Head of International Regulatory Policy, Pfizer | |
| Dr Jacques Mascaro | Senior Vice President, Oncology Regulatory Science, Strategy and Excellence, AstraZeneca | |
| Eddie Reilly | Chief Regulatory Officer, Sanofi | |
| Jerry Stewart | Vice President, Regulatory Policy & Advocacy Head, GlaxoSmithKline | |
| Natalie Tolli | Vice President, Regulatory Affairs (Regulatory International, Regulatory Policy & Intelligence), Abbvie | |
| Dr Max Wegner | Senior Vice President, Head of Regulatory Affairs, Bayer | |
| Anna Somuyiwa | Head, CIRS | |
| Dr Neil McAuslane | Director, CIRS | |
| Prof Stuart Walker | Founder and Senior Advisor, CIRS | |
| Specialist Advisors | ||
|---|---|---|
| Dr Thomas Lönngren | Independent Strategy Advisor, PharmaExec Consulting Filial SE, Sweden, and Former Executive Director, EMA | |
| Dr Murray Lumpkin | Deputy Director, Integrated Development, and Lead for Global Regulatory Systems Initiatives, Bill and Melinda Gates Foundation | |
| Prof Mamoru Narukawa | Professor, Pharmaceutical Medicine, Kitasato University Graduate School of Pharmaceutical Sciences, Japan | |
| Dr Tomas Salmonson | Partner, Consilium Salmonson & Hemmings and Former Chair, CHMP/EMA | |
| Dr Joseph Scheeren | Former President and CEO, Critical Path Institute | |
| HTA Steering Committee | ||
|---|---|---|
| Chair: Dr Brian O’Rourke | Former CEO and President, CADTH, Canada | |
| Vice-Chair: Prof Adrian Towse | Director Emeritus and Senior Research Fellow, Office of Health Economics (OHE), UK | |
| Dr Michael Coory | Medical Advisor, Technology Access and Assessment Division, Commonwealth Department of Health, Australia | |
| Dr Nick Crabb | Programme Director, Scientific Affairs, National Institute for Health and Care Excellence (NICE), UK | |
| Prof Hans-Georg Eichler | Consulting Physician of the Association of Austrian Social Insurance Institutions | |
| Dr Wim Goettsch | Professor HTA, Utrecht University and Special Advisor HTA, National Health Care Institute (ZIN), The Netherlands | |
| Niklas Hedberg | Chief Pharmacist, Dental and Pharmaceutical Benefits Agency (TLV), Sweden | |
| Suzanne McGurn | CEO and President, CADTH, Canada | |
| Dr Detlev Parow | Former Head, Department of Medicines, Medical Remedies and Selective Contracts, DAK – Gesundheit, German | |
| Dr Anja Schiel | Special Adviser, Lead Methodologist in Regulatory and Pharmacoeconomic Statistics, Norwegian Medicines Agency (NoMA); Vice-Chair JSC (EUnetHTA21) | |
| Dr Indranil Bagchi | Global Head, Pricing & Market Access, GSK | |
| Lucia D’Apote | Executive Director of ELMAC & JAPAC within Global Regulatory and R&D Policy, Amgen | |
| Ramiro Gilardino | Global HTA & Access Policy Lead – Global Market Access, MSD | |
| Adrian Griffin | Vice President for HTA Policy, Johnson & Johnson | |
| Dr Adam Heathfield | Senior Director, Patient and Health Impact Innovation Centre, Pfizer | |
| Dr Michael Happich | Senior Director HTA, International markets, Eli Lilly and Co | |
| Dr Vanessa Elisabeth Schaub | Global Access Chapter Lead for Evidence, Roche | |
| Prof Finn Børlum Kristensen | Professor of Health Services Research and HTA, Faculty of Health Sciences, University of Southern Denmark and Former Director and Chair of EUnetHTA Executive Committee | |
| Prof Andrew Mitchell | Honorary Professor, The Australian National University | |
| Dr Sean Tunis | Principal, Rubix Health | |
| Anna Somuyiwa | Head, CIRS | |
| Dr Neil McAuslane | Director, CIRS | |
| Dr Tina Wang | Senior Manager, HTA Programme and Strategic Partnerships | |